Development and Validation of RP-HPLC Method for the Determination of Dimercaprol Drug

Abstract

The purpose of this study is to develop and validate a reverse-phase high-performance liquid chromatography (RP-HPLC) method for the determination of Dimercaprol (British anti-lewisite, BAL), an essential chelating agent used for the treatment of heavy metal poisoning. Dimercaprol is known to bind to metal ions like arsenic, mercury, and lead, facilitating their excretion from the body. A suitable RP-HPLC method is crucial for ensuring the drug's quality, stability, and appropriate dosage during clinical use. In this study, we describe the development and optimization of the RP-HPLC method, including the selection of the mobile phase, column, and detection conditions. Validation of the method was carried out in accordance with ICH guidelines, demonstrating its specificity, precision, accuracy, and robustness[2-3]

HPLC method development for Dimercaprol is a well-established area, but there are still multiple opportunities for innovative contributions. By focusing on enhancing sensitivity, improving data analysis techniques, optimizing formulations, exploring green chemistry approaches, and developing more accessible therapeutic monitoring systems, you can provide new insights and contribute to advancing the clinical and pharmaceutical applications of dimercaprol. We can explore new detection techniques or enhanced sensitivity methods such as Coupling HPLC with Mass Spectrometry (HPLC-MS), Development of More Sensitive[1-2] UV or Fluorescence Detectors, Novel Mobile Phase or Stationary Phase Optimization, Integration with Advanced Data Analysis Techniques, Alternative Drug Delivery Systems (DDS).The development of a High-Performance Liquid Chromatography (HPLC) method involves focusing on purity analysis, quantification in dosage forms, pharmacokinetic studies, or therapeutic drug monitoring.

Keywords: Dimercaprol, RP-HPLC, Method Development, Validation, Drug Analysis, Chelating Agent